Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression

Zarina J D'Costa, Cheng M Leong, Justin Shields, Charles Matthews, Merilyn H Hibma

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Summary Persistent infections with certain high-risk human papillomavirus (HPV) types such as 16 and 18 can result in the development of cervical cancer. Neither of the two prophylactic vaccines against HPV16 and 18 that are in current use have any therapeutic efficacy for prevalent HPV infections. Ablative therapy is widely used for the treatment of HPV cervical dysplasia however disease recurrence is a widely recognized problem. Thus there is a continuing need for therapeutic approaches for the treatment of HPV infections. The HPV16 E6 viral oncoprotein represses surface expression of the cellular adhesion molecule, E-cadherin. Reduced E-cadherin expression on HPV-infected keratinocytes is associated with lowered numbers of antigenpresenting Langerhans cells in the infected epidermis, potentially reducing immune surveillance for HPV. Four chemicals reported to up-regulate E-cadherin were screened..............................
Original languageEnglish
Pages (from-to)2236 - 2251
Number of pages16
JournalInvestigational New Drugs
Issue number6
Publication statusPublished - 2012
Externally publishedYes

Cite this